Drug reference
tremelimumab
human IgG2 monoclonal antibody, CTLA-4 inhibitor, immune checkpoint inhibitor · anticancer, immunomodulator
human IgG2 monoclonal antibody, CTLA-4 inhibitor, immune checkpoint inhibitoranticancer, immunomodulator
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Tremelimumab is a human IgG2 monoclonal antibody that targets CTLA-4.
Indications
malignant mesothelioma (orphan drug designation, under investigation in clinical trials)
Related guidelines
Ask House about tremelimumab
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10